The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Median Maximal Drug Concentration (Cmax)
Timeframe: 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose